- Previous Close
4.95 - Open
5.04 - Bid --
- Ask 5.27 x 200
- Day's Range
4.75 - 5.66 - 52 Week Range
3.34 - 11.45 - Volume
105,121 - Avg. Volume
48,421 - Market Cap (intraday)
82.006M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.44 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
elicio.comRecent News: ELTX
View MorePerformance Overview: ELTX
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELTX
View MoreValuation Measures
Market Cap
78.52M
Enterprise Value
78.55M
Trailing P/E
5.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.70%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.84M
Diluted EPS (ttm)
-3.44
Balance Sheet and Cash Flow
Total Cash (mrq)
26.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.21M